For the first time, research is being conducted to transform the diagnosis and treatment of HE. HESA is partnering with Dr. Ahmed Obeidat, a leading expert at the Medical College of Wisconsin, to conduct a groundbreaking study to improve outcomes for HE patients worldwide. Why does this research matter? The diagnosis of HE is made difficult because there is, to date, no definitive test to establish it. For those who receive a diagnosis of HE, treatment usually involves immunosuppression, but treatment protocols are not universal, and in many cases, patients cannot obtain insurance approval for the more costly treatment protocols that become necessary when first-line treatments fail, with insurers classifying such treatments as “experimental” or “unproven” due to the lack of studies establishing their efficacy. Dr. Obeidat believes HE is under-studied, under-recognized, and under-diagnosed. As a result, he has observed that many HE patients do not receive proper care. He is dedicated to improving the medical diagnosis and treatment of HE, including long-term patient management. With your support, we can: - Identify the frequency and nature of abnormal diagnostic tests in HE patients. - Understand the factors influencing treatment decisions and outcomes. - Compare markers of neural damage in HE patients and controls. - Develop an educational curriculum for healthcare professionals. - Create no-cost educational materials for patients and families. This is the first study of its kind, and its findings have the potential to revolutionize how HE is diagnosed and treated, improving the lives of countless patients. HESA receives no government funding and relies entirely on donations to make this research possible. We aim to raise $10,000 to fund this critical study. Every dollar brings us closer to: - Providing hope for patients and families. - Equipping doctors with the tools they need to deliver better care. - Advancing understanding of a disease that has been overlooked for too long. Donate today. Your support can change lives. Together, we can create a future where HE patients receive timely diagnoses, effective treatments, and the chance to reclaim their lives.